Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Peptide nucleic acid-dependent artifact can lead to false-positive triplex gene editing signals.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 20, 2021
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: February 02, 2017
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 19, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 28, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: May 13, 2016
Current status and prospects of HIV treatment.
Journal: Current opinion in virology
Published: February 24, 2016
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Journal: HIV clinical trials
Published: February 20, 2016
Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 18, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 02, 2016
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Journal: Antimicrobial agents and chemotherapy
Published: January 03, 2016
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: December 03, 2015
Last Updated: 09/26/2026